Ozempic Side Effects: A 2026 Canadian Guide for Patients
Ozempic side effects are the number one concern Canadians raise before starting or continuing semaglutide — and rightly so. While most patients tolerate the medication well, gastrointestinal symptoms affect roughly one in four during titration, and a smaller fraction experience gallbladder, pancreatic, or thyroid-related concerns flagged by Health Canada and the U.S. FDA. This evidence-based guide, reviewed by a CPSA-registered Canadian physician, walks through every documented side effect, how often it actually happens, what to do at home, and the red-flag symptoms that mean you should call 811, your virtual doctor, or 911 right away.
Book Your Appointment Now
Ozempic (semaglutide) most commonly causes nausea, vomiting, diarrhea, or constipation in 20-30% of Canadian patients during titration, with symptoms typically resolving within 4-8 weeks. Rarer but serious risks listed by Health Canada include pancreatitis (<1%), gallbladder disease (~1.5-2%), and thyroid C-cell tumours (black-box warning). Severe abdominal pain, persistent vomiting, or signs of an allergic reaction warrant immediate medical care.
- Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) occur in roughly 20-30% of patients during dose titration, per Health Canada-cited SUSTAIN trial data.
- Pancreatitis is reported in fewer than 1% of GLP-1 receptor agonist users; Health Canada and the U.S. FDA include a related warning in the Ozempic product monograph.
- Gallbladder events such as cholecystitis and cholelithiasis were reported in approximately 1.5-2% of semaglutide users over 68 weeks in the STEP and SUSTAIN trial programs.
- Most gastrointestinal symptoms resolve within 4-8 weeks of dose stabilization, and titration pacing is the single most effective tolerability strategy.
What Ozempic Does in the Body — and Why That Causes Side Effects
Ozempic is the brand name for semaglutide, a once-weekly injectable GLP-1 receptor agonist manufactured by Novo Nordisk and approved by Health Canada in January 2018. It mimics glucagon-like peptide-1, a gut hormone released after meals. Three of its actions explain almost every side effect you'll read about. First, it slows gastric emptying, which is the direct cause of nausea, fullness, reflux, and constipation. Second, it amplifies insulin release in response to glucose, which can occasionally produce hypoglycemia when stacked on insulin or sulfonylureas. Third, GLP-1 receptors are expressed not only in the gut and pancreas but also in the gallbladder, thyroid C cells, and central nervous system, which explains the less common but clinically important warnings discussed below.
The Most Common Ozempic Side Effects (Gastrointestinal)
Across Health Canada's product monograph and the SUSTAIN, STEP, and PIONEER clinical trial programs, gastrointestinal symptoms are by far the most frequently reported issues. They cluster in the first 8 to 12 weeks of treatment and during each dose increase. Frequency varies by dose: at 0.5 mg the rates are lower, at 1 mg and 2 mg they are higher.
- Nausea — reported by approximately 15-20% of patients, peaking in the first 4 weeks after each dose increase.
- Vomiting — affects roughly 5-9% of users, usually mild and intermittent.
- Diarrhea — reported by 8-9% of patients on the 1 mg dose.
- Constipation — affects 3-5%, often related to reduced fluid and fibre intake from smaller meals.
- Abdominal pain or discomfort — typically mild, but persistent or severe pain warrants assessment for pancreatitis or gallbladder disease.
- Burping, reflux, and bloating — common during titration, generally improve as the body adapts.
How to Manage Ozempic GI Side Effects at Home
Most gastrointestinal complaints do not require stopping Ozempic. Practical changes resolve the majority of cases within a few weeks. If symptoms persist beyond 8 weeks at a stable dose, escalate or interrupt the dose only with your prescriber's input — never stop a GLP-1 medication abruptly mid-titration without guidance.
- Eat smaller, more frequent meals — large plates trigger nausea because gastric emptying is already slowed.
- Stop eating at the first sign of fullness; the satiety signal is amplified on Ozempic.
- Hydrate aggressively — aim for 2 to 2.5 litres of water daily; dehydration worsens nausea, constipation, and kidney strain.
- Use the BRAT pattern (bananas, rice, applesauce, toast) on the worst days, then layer in lean protein and soluble fibre.
- Avoid high-fat, fried, or very spicy meals during titration — they delay emptying further.
- Limit alcohol — it irritates the stomach lining and adds to nausea risk.
- Discuss dose pacing with your physician; many Canadian prescribers extend each titration step from 4 weeks to 6-8 weeks if tolerability is poor.
Pancreatitis: A Rare but Serious Warning
Health Canada and the U.S. FDA both include a warning about acute pancreatitis in the Ozempic product monograph. Across pooled GLP-1 trials, pancreatitis is reported in less than 1% of users, but it is potentially life-threatening and requires immediate emergency care. Risk factors include a personal history of pancreatitis, gallstones, heavy alcohol use, and very high triglycerides. The classic presentation is sudden severe upper abdominal pain that radiates to the back, often with persistent vomiting. If you experience this combination, stop the medication, do not eat or drink, and go to the nearest emergency department or call 911.
Gallbladder Issues: Cholecystitis and Gallstones
Rapid weight loss of any cause increases gallstone risk, and GLP-1 medications are independently associated with gallbladder disease. In the STEP and SUSTAIN programs, cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) were reported in roughly 1.5 to 2% of semaglutide users over 68 weeks — modestly higher than placebo. The mechanism is multifactorial: slowed gallbladder emptying, altered bile composition, and rapid fat-mass loss. Watch for severe right-upper-quadrant pain (especially after fatty meals), pain referred to the right shoulder blade, fever, jaundice (yellow skin or eyes), or pale stools with dark urine. These warrant same-day medical evaluation, abdominal ultrasound, and bloodwork.
Hypoglycemia Risk: Mostly a Combination Drug Issue
Used on its own, Ozempic rarely causes low blood sugar because its insulin-releasing effect is glucose-dependent — it only kicks in when blood sugar is elevated. The risk rises sharply when it is combined with insulin or sulfonylureas (glyburide, gliclazide, glimepiride). Your Canadian prescriber will typically reduce those background medications when starting semaglutide. Symptoms of hypoglycemia include shakiness, sweating, palpitations, hunger, confusion, and in severe cases, loss of consciousness. Treat with 15 grams of fast-acting carbohydrate (juice, glucose tablets), recheck in 15 minutes, and follow with a snack containing protein. If you live alone and use insulin, talk to your doctor about a glucagon emergency kit.
Thyroid C-Cell Tumours: The Black-Box Warning
Ozempic carries a Health Canada and U.S. FDA boxed warning for thyroid C-cell tumours, based on rodent studies in which semaglutide caused medullary thyroid carcinoma. Whether this risk translates to humans remains unproven — surveillance through 2025 has not demonstrated a definitive causal link in patients — but the precautionary contraindication is firm. Ozempic must NOT be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Tell your prescriber immediately if you notice a lump or swelling in your neck, persistent hoarseness, difficulty swallowing, or shortness of breath that develops while on Ozempic. These warrant a thyroid ultrasound and calcitonin blood test.
Injection-Site Reactions and Rare Allergic Responses
Local reactions at the injection site are common but mild — typically transient redness, itching, or a small bump that fades within a day or two. Rotating injection sites between abdomen, thigh, and upper arm reduces irritation. Severe allergic (anaphylactic) reactions are rare with semaglutide but have been reported and were highlighted in a 2022 Health Canada safety review. Stop the medication and call 911 if you develop hives, swelling of the face, lips or tongue, throat tightness, wheezing, or sudden severe rash after an injection. Patients with a known prior allergy to GLP-1 medications should not take Ozempic.
Mental Health and Mood: What the Recent Reviews Actually Say
In 2023, both Health Canada and the European Medicines Agency (EMA) opened reviews into reports of suicidal ideation and self-harm in GLP-1 users. As of the EMA's April 2024 conclusion and ongoing FDA monitoring, no causal link between semaglutide and suicidal thoughts has been established, and large observational studies (Lancet Diabetes & Endocrinology, 2024) have not shown an increased risk versus other weight-management approaches. That said, mood changes can occur with any major metabolic shift, and rapid weight loss itself can affect mental health. Tell your physician if you notice persistent low mood, anxiety, sleep changes, or any thoughts of self-harm. If you are in crisis, call or text 9-8-8 — Canada's Suicide Crisis Helpline — available 24/7 nationwide. Mental health follow-up is part of routine virtual care at TelePlus Care.
Long-Term Unknowns: Muscle Loss, Weight Regain, and Data Beyond 68 Weeks
Most randomized controlled trials of semaglutide for weight management have run 68 weeks (STEP-1 through STEP-8). Real-world follow-up beyond two years is still accumulating. Three long-term concerns deserve honest discussion with your physician. First, lean muscle mass loss: an estimated 25-40% of weight lost on GLP-1 medications is from lean tissue, including muscle, unless resistance training and adequate protein intake (1.2-1.6 g/kg/day) are prioritized. Second, weight regain on discontinuation: the STEP-1 extension study showed roughly two-thirds of lost weight is regained within 12 months of stopping. Third, the cardiovascular and cancer profile beyond 5 years is still being studied; the SELECT trial (2023) is reassuring for cardiovascular outcomes but ongoing surveillance continues.
Who Should NOT Take Ozempic — Absolute and Relative Contraindications
Some Canadians should not take Ozempic at all, while others require careful risk-benefit discussion. Your virtual or in-person prescriber will screen for these before issuing the first prescription. Bring a complete medication list and personal and family medical history to your consultation.
- Personal or family history of medullary thyroid carcinoma (MTC) — absolute contraindication.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN-2) — absolute contraindication.
- Known hypersensitivity to semaglutide or any product excipient.
- Pregnancy or planning pregnancy within 2 months — discontinue at least 8 weeks before conception.
- Breastfeeding — not recommended; safety data are insufficient.
- Severe gastroparesis or significant pre-existing GI motility disorder.
- End-stage renal disease (eGFR <15) or severe hepatic impairment — limited safety data.
- Active or prior pancreatitis — relative contraindication; specialist input recommended.
- Type 1 diabetes — Ozempic is not a substitute for insulin and is not approved for type 1.
- Children under 18 — Ozempic is not Health Canada approved for pediatric use.
When to Call Your Doctor — and When to Go to the ER
Knowing which symptoms can be managed at home, which need a same-week appointment, and which require emergency care is the most important part of safe Ozempic use. Save your virtual clinic's contact and Health Link 811 in your phone before your first dose.
- Call 911 or go to the ER: severe abdominal pain radiating to the back, persistent vomiting with inability to keep fluids down, signs of anaphylaxis (face/throat swelling, breathing trouble), or new severe right-upper-quadrant pain with fever or jaundice.
- Same-day or next-day medical review: persistent vomiting beyond 24 hours, signs of dehydration, blood sugar consistently below 4.0 mmol/L, neck lump, or persistent hoarseness.
- Routine follow-up with your prescriber (within 1-2 weeks): GI symptoms not improving by week 8, mood changes, fatigue, or questions about dose pacing.
- Mental health crisis support: call or text 9-8-8 (Canada's Suicide Crisis Helpline) anytime, 24/7.
- After-hours non-urgent advice in Alberta: dial 811 for Health Link nurse triage.
Talk to a Canadian-Licensed Physician About Your Ozempic Concerns
If you are starting Ozempic, mid-titration, or weighing whether to continue, a virtual consultation with a CPSA-registered physician at TelePlus Care can review your symptoms, adjust your dose pacing, order labs, and coordinate with your pharmacy — usually within 24 to 48 hours. Our physicians follow Health Canada, Diabetes Canada, and Obesity Canada guidance and document every visit so your family doctor stays in the loop. Side effects are manageable for most patients with the right support; you don't need to push through alone.
Your Fast and Convenient Healthcare Solution
Connect with a licensed healthcare provider from the comfort of your home. No referral needed — book your virtual appointment today.
Book Your Appointment Now
Serving Communities Across Alberta
Available to adults across Alberta (Edmonton, Calgary, Red Deer, Lethbridge, Medicine Hat, Fort McMurray, Grande Prairie, Airdrie) and select Canadian provinces through licensed virtual physician care.
Teleplus care clinic is not an urgent care clinic. If you have an emergency please call 911 or go to the nearest urgent care facility.
